Global Oncology Clinical Trials Market Projected to Reach US$ 25.61 Billion by 2035, Supported by Advances in Precision and Targeted Therapies Says Astute Analytica

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• North America accounted for over 41.58% revenue share of the oncology clinical trials market

  80% confidence

• Spending on cancer medicines will reach USD 441 billion by 2029

  80% confidence

• Novel modalities, including ADCs and Cell/Gene therapies, accounted for 35% of all oncology trial starts in 2024

  80% confidence

• 2,162 oncology clinical trials were initiated globally in 2024, representing a 12-unit increase on an index basis compared to 2019 levels

  80% confidence

• Global spending on cancer medicines reached USD 252 billion in 2024, reflecting a USD 29 billion increase from the previous year

  80% confidence

• The global oncology clinical trials market is projected to hit the market valuation of USD 25.61 billion by 2035 from USD 14.95 billion in 2025 at a CAGR of 5.53% during the forecast period 2026–2035

  80% confidence

• Asia-Pacific is projected to witness the fastest CAGR from 2025 to 2034

  80% confidence

• A 160% increase in pancreatic cancer survival rates was reported in 2024 due to clinical trial advancements

  80% confidence

• Biosimilars in oncology generated USD 7 billion in savings for payers in 2023/2024, with cumulative savings reaching USD 19 billion since 2017

  80% confidence

• The probability of technical success for ADC monotherapies in Phase III is 53%, higher than the general oncology average

  80% confidence

• The number of oncology Novel Active Substances (NAS) launched globally in the 5-year period ending 2024 reached 132

  80% confidence

Data points we hold from this source